Tag Archives: RE-LY

Pradaxa Is Effective in All Types of Atrial Fibrillation

Posted on May 15, 2011 by wngai

A new subgroup analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial Treatment indicated that the 150mg twice daily dose of dabigatran (Pradaxa) is equally safe and effective in patients with permanent, persistent, and paroxysmal atrial fibrillation.  Dabigatran … Continue reading →

Posted in Arrhythmia, Cardiovascular disease | Tagged , , , , , , | Comments Off on Pradaxa Is Effective in All Types of Atrial Fibrillation

New Drug to Prevent Future Strokes

Posted on November 22, 2010 by wngai

As we all knew, patients who have a stroke or a transient ischemic attack have more than double the risk of having another attack. Now a subanalysis of RE-LY study which was published in The Lancet Neurology indicated that dabigatran … Continue reading →

Posted in Cardiovascular disease, Stroke | Tagged , , , , , , | Comments Off on New Drug to Prevent Future Strokes

Pradaxa eliminates the need to monitor INR in Atrial Fibrillation patients

Posted on April 25, 2010 by wngai

Good news for atrial fibrillation (AF) patients who require taking warfarin to prevent stroke.  It is well known that routine blood monitor and food interaction represent major hassles for patients taking warfrin. However, a new drug, Pradaxa (dabigatran), might be … Continue reading →

Posted in Arrhythmia, Cardiovascular disease | Tagged , , , , | Comments Off on Pradaxa eliminates the need to monitor INR in Atrial Fibrillation patients